Estrella Capital Stock from 2010 to 2024

ESLAW Stock   0.09  0  3.53%   
Estrella Immunopharma Capital Stock yearly trend continues to be fairly stable with very little volatility. Capital Stock will likely drop to 3,478 in 2024. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals
 
Capital Stock  
First Reported
2010-12-31
Previous Quarter
3.7 K
Current Value
3.5 K
Quarterly Volatility
1.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Estrella Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Estrella Immunopharma's main balance sheet or income statement drivers, such as Tax Provision of 1.7 K, Depreciation And Amortization of 246.2 K or Selling General Administrative of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 8.39. Estrella financial statements analysis is a perfect complement when working with Estrella Immunopharma Valuation or Volatility modules.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Latest Estrella Immunopharma's Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Estrella Immunopharma over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Estrella Immunopharma's Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Estrella Immunopharma's overall financial position and show how it may be relating to other accounts over time.
Capital Stock10 Years Trend
Slightly volatile
   Capital Stock   
       Timeline  

Estrella Capital Stock Regression Statistics

Arithmetic Mean333,817
Geometric Mean0.00
Coefficient Of Variation386.71
Mean Deviation622,171
Median0.00
Standard Deviation1,290,888
Sample Variance1.7T
Range5M
R-Value0.31
Mean Square Error1.6T
R-Squared0.1
Significance0.26
Slope89,453
Total Sum of Squares23.3T

Estrella Capital Stock History

2024 3477.95
2023 3661.0
2022M
2021 18.0

Other Fundumenentals of Estrella Immunopharma

Estrella Immunopharma Capital Stock component correlations

About Estrella Immunopharma Financial Statements

Estrella Immunopharma investors use historical fundamental indicators, such as Estrella Immunopharma's Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Estrella Immunopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Stock3.7 K3.5 K
Issuance Of Capital StockM9.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Estrella Stock Analysis

When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.